{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:58:40Z","timestamp":1793091520016,"version":"4.5.0"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100005969","name":"Universit\u00e0 di Bologna","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005969","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ejim.2020.07.006","type":"journal-article","created":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T08:31:42Z","timestamp":1596011502000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":421,"special_numbering":"C","title":["Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Agabiti-Rosei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan T.","family":"Kielstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Empar","family":"Lurbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mancia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Redon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin G.","family":"Stack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos P.","family":"Tsioufis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2020.07.006_bib0001","series-title":"Encyclopedia of molecular mechanisms of disease","first-page":"956","article-title":"Hyperuricemia","author":"Becker","year":"2009"},{"key":"10.1016\/j.ejim.2020.07.006_bib0002","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/BOR.0000000000000028","article-title":"Definition of hyperuricemia and gouty conditions","volume":"26","author":"Bardin","year":"2014","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0003","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1523-1755.2005.00074.x","article-title":"Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats","volume":"67","author":"Sanchez-Lozada","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2020.07.006_bib0004","doi-asserted-by":"crossref","first-page":"e50046","DOI":"10.1371\/journal.pone.0050046","article-title":"Reduced glomerular function and prevalence of gout: NHANES 2009-10","volume":"7","author":"Krishnan","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejim.2020.07.006_bib0005","first-page":"301","article-title":"Trends in hyperuricemia and gout prevalence: nutrition and Health Survey in Taiwan from 1993\u20131996 to 2005-2008","volume":"20","author":"Chuang","year":"2011","journal-title":"Asia Pac J Clin Nutr"},{"key":"10.1016\/j.ejim.2020.07.006_bib0006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7326\/0003-4819-131-1-199907060-00003","article-title":"Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study","volume":"131","author":"Culleton","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2020.07.006_bib0007","first-page":"1859","article-title":"Dietary and lifestyle changes associated with high prevalence of hyperuricemia and gout in the Shandong coastal cities of Eastern China","volume":"35","author":"Miao","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0008","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2011-201254","article-title":"Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study","volume":"72","author":"Trifiro","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2020.07.006_bib0009","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ejim.2020.07.006_bib0010","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/bmj.1.5851.449","article-title":"Effect of oestrogen therapy on plasma and urinary levels of uric acid","volume":"1","author":"Nicholls","year":"1973","journal-title":"Br Med J"},{"key":"10.1016\/j.ejim.2020.07.006_bib0011","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/01.HYP.0000069700.62727.C5","article-title":"Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?","volume":"41","author":"Johnson","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2020.07.006_bib0012","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semnephrol.2011.08.004","article-title":"The epidemiology of uric acid and fructose","volume":"31","author":"Rho","year":"2011","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0013","first-page":"1295","article-title":"Is it time to revise the normal range of serum uric acid levels?","volume":"18","author":"Desideri","year":"2014","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.ejim.2020.07.006_bib0014","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1001\/archinte.1987.00370040027005","article-title":"Is thiazide-produced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program","volume":"147","author":"Langford","year":"1987","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2020.07.006_bib0015","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1007\/s10067-017-3851-y","article-title":"Asymptomatic hyperuricemia: is it time to intervene?","volume":"36","author":"Paul","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0016","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.semnephrol.2004.09.007","article-title":"Uric acid as a mediator of endothelial dysfunction, inflammation, and vascular disease","volume":"25","author":"Kanellis","year":"2005","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0017","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1378\/chest.06-2235","article-title":"Endogenous urate production augments plasma antioxidant capacity in healthy lowland subjects exposed to high altitude","volume":"131","author":"Baillie","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2020.07.006_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1000504","article-title":"Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations","volume":"5","author":"Kolz","year":"2009","journal-title":"PLoS Genet"},{"key":"10.1016\/j.ejim.2020.07.006_bib0019","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/CIRCGENETICS.109.934455","article-title":"Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors","volume":"3","author":"Yang","year":"2010","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.ejim.2020.07.006_bib0020","doi-asserted-by":"crossref","first-page":"40732","DOI":"10.1074\/jbc.M112.399899","article-title":"Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver","volume":"287","author":"Lanaspa","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejim.2020.07.006_bib0021","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1042\/bj1190501","article-title":"The cause of hepatic accumulation of fructose 1-phosphate on fructose loading","volume":"119","author":"Woods","year":"1970","journal-title":"Biochem J"},{"key":"10.1016\/j.ejim.2020.07.006_bib0022","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1046\/j.1365-2362.1997.1390687.x","article-title":"Antioxidant status in patients with uncomplicated insulin-dependent and non-insulin-dependent diabetes mellitus","volume":"27","author":"Maxwell","year":"1997","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.ejim.2020.07.006_bib0023","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1161\/01.HYP.0000072820.07472.3B","article-title":"Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2","volume":"41","author":"Kanellis","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2020.07.006_bib0024","first-page":"1207","article-title":"Blood coagulation and platelet economy in subjects with primary gout","volume":"89","author":"Mustard","year":"1963","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.ejim.2020.07.006_bib0025","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1016\/S0021-9258(18)93017-6","article-title":"Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression","volume":"266","author":"Rao","year":"1991","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejim.2020.07.006_bib0026","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/HJH.0b013e328337da1d","article-title":"Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction","volume":"28","author":"Yu","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2020.07.006_bib0027","doi-asserted-by":"crossref","first-page":"F1134","DOI":"10.1152\/ajprenal.00104.2008","article-title":"Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia","volume":"295","author":"Sanchez-Lozada","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0028","doi-asserted-by":"crossref","first-page":"F1238","DOI":"10.1152\/ajprenal.00164.2006","article-title":"Effects of acute and chronic l-arginine treatment in experimental hyperuricemia","volume":"292","author":"Sanchez-Lozada","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0029","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1096\/fj.13-243634","article-title":"Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids","volume":"28","author":"Cicerchi","year":"2014","journal-title":"FASEB J"},{"key":"10.1016\/j.ejim.2020.07.006_bib0030","doi-asserted-by":"crossref","first-page":"e48801","DOI":"10.1371\/journal.pone.0048801","article-title":"Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver","volume":"7","author":"Lanaspa","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejim.2020.07.006_bib0031","doi-asserted-by":"crossref","first-page":"e47948","DOI":"10.1371\/journal.pone.0047948","article-title":"Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver","volume":"7","author":"Lanaspa","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejim.2020.07.006_bib0032","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1080\/15257770600890772","article-title":"Purine catabolism in advanced carotid artery plaque","volume":"25","author":"Felici","year":"2006","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.ejim.2020.07.006_bib0033","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1440-1797.2011.01513.x","article-title":"Uric acid and incident chronic kidney disease in a large health check-up population in Taiwan","volume":"16","author":"Wang","year":"2011","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ejim.2020.07.006_bib0034","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJM196609012750902","article-title":"Hyperuricemia in primary and renal hypertension","volume":"275","author":"Cannon","year":"1966","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2020.07.006_bib0035","doi-asserted-by":"crossref","first-page":"e56546","DOI":"10.1371\/journal.pone.0056546","article-title":"Dose-response association of uncontrolled blood pressure and cardiovascular disease risk factors with hyperuricemia and gout","volume":"8","author":"Juraschek","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejim.2020.07.006_bib0036","doi-asserted-by":"crossref","first-page":"e4177","DOI":"10.1097\/MD.0000000000004177","article-title":"Hyperuricemia and uncontrolled hypertension in treated hypertensive patients: k-MetS Study","volume":"95","author":"Cho","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejim.2020.07.006_bib0037","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejim.2016.07.026","article-title":"High serum uric acid is associated to poorly controlled blood pressure and higher arterial stiffness in hypertensive subjects","volume":"37","author":"Cicero","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2020.07.006_bib0038","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijcard.2016.05.044","article-title":"Lack of control of hypertension in primary cardiovascular disease prevention in Europe: results from the EURIKA study","volume":"218","author":"Borghi","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0039","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1291\/hypres.27.835","article-title":"Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan","volume":"27","author":"Nagahama","year":"2004","journal-title":"Hypertens Res"},{"key":"10.1016\/j.ejim.2020.07.006_bib0040","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/acr.20344","article-title":"Hyperuricemia and incident hypertension: a systematic review and meta-analysis","volume":"63","author":"Grayson","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ejim.2020.07.006_bib0041","article-title":"Hyperuricemia and risk of incident hypertension: a systematic review and meta-analysis of observational studies","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejim.2020.07.006_bib0042","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nrneph.2010.125","article-title":"Could uric acid have a pathogenic role in pre-eclampsia?","volume":"6","author":"Martin","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0043","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1471-0528.2006.00908.x","article-title":"Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review","volume":"113","author":"Thangaratinam","year":"2006","journal-title":"BJOG"},{"key":"10.1016\/j.ejim.2020.07.006_bib0044","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1161\/01.HYP.0000085858.66548.59","article-title":"Hyperuricemia in childhood primary hypertension","volume":"42","author":"Feig","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2020.07.006_bib0045","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/ard.28.4.374","article-title":"Dietes mellitus and gout. Blood sugar and plasma insulin responses to oral glucose in normal weight, overweight, and gouty patients","volume":"28","author":"Boyle","year":"1969","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2020.07.006_bib0046","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1097\/HJH.0000000000000701","article-title":"Serum uric acid and the risk of cardiovascular and renal disease","volume":"33","author":"Borghi","year":"2015","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2020.07.006_bib0047","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.amjmed.2006.06.040","article-title":"Prevalence of the metabolic syndrome in individuals with hyperuricemia","volume":"120","author":"Choi","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2020.07.006_bib0048","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10654-013-9829-4","article-title":"Association between serum uric acid and the metabolic syndrome among a middle- and old-age Chinese population","volume":"28","author":"Dai","year":"2013","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0049","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/09513590.2016.1214261","article-title":"The relationship between serum uric acid and metabolic syndrome in premenopausal and postmenopausal women in the Jinchang Cohort","volume":"33","author":"He","year":"2017","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0050","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40200-015-0200-z","article-title":"Association between serum uric acid level and metabolic syndrome components","volume":"14","author":"Nejatinamini","year":"2015","journal-title":"J Diabetes Metab Disord"},{"key":"10.1016\/j.ejim.2020.07.006_bib0051","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s00380-013-0386-2","article-title":"Serum uric acid is an independent predictor of metabolic syndrome in a Japanese health screening population","volume":"29","author":"Oda","year":"2014","journal-title":"Heart Vessels"},{"key":"10.1016\/j.ejim.2020.07.006_bib0052","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12872-015-0059-4","article-title":"The association between serum uric acid levels, metabolic syndrome and cardiovascular disease in middle aged and elderly Chinese: results from the DYSlipidemia International Study","volume":"15","author":"Tian","year":"2015","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ejim.2020.07.006_bib0053","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.metabol.2008.01.030","article-title":"Uric acid and the development of metabolic syndrome in women and men","volume":"57","author":"Sui","year":"2008","journal-title":"Metabolism"},{"key":"10.1016\/j.ejim.2020.07.006_bib0054","doi-asserted-by":"crossref","first-page":"14325","DOI":"10.1038\/srep14325","article-title":"Dose-response relationship of serum uric acid with metabolic syndrome and non-alcoholic fatty liver disease incidence: a meta-analysis of prospective studies","volume":"5","author":"Liu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejim.2020.07.006_bib0055","doi-asserted-by":"crossref","first-page":"e89696","DOI":"10.1371\/journal.pone.0089696","article-title":"Uric acid is associated with metabolic syndrome in children and adults in a community: the Bogalusa Heart Study","volume":"9","author":"Sun","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejim.2020.07.006_bib0056","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143786","article-title":"Uric acid levels can predict metabolic syndrome and hypertension in adolescents: a 10-year longitudinal study","volume":"10","author":"Sun","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejim.2020.07.006_bib0057","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2042018817732731","article-title":"Serum uric acid levels are associated with homeostasis model assessment in obese nondiabetic patients: HOMA and uric acid","volume":"8","author":"Elizalde-Barrera","year":"2017","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.ejim.2020.07.006_bib0058","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.2337\/dc09-0288","article-title":"Association between serum uric acid and development of type 2 diabetes","volume":"32","author":"Kodama","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2020.07.006_bib0059","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jch.12434","article-title":"Association of hyperuricemia with conventional cardiovascular risk factors in elderly patients","volume":"17","author":"Marotta","year":"2015","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.ejim.2020.07.006_bib0060","doi-asserted-by":"crossref","first-page":"e56864","DOI":"10.1371\/journal.pone.0056864","article-title":"High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies","volume":"8","author":"Lv","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejim.2020.07.006_bib0061","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.2337\/db14-0742","article-title":"A mendelian randomization study of circulating uric acid and type 2 diabetes","volume":"64","author":"Sluijs","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.ejim.2020.07.006_bib0062","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1047-2797(99)00037-X","article-title":"Serum uric acid and risk of coronary heart disease: atherosclerosis Risk in Communities (ARIC) Study","volume":"10","author":"Moriarity","year":"2000","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0063","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1371\/journal.pmed.0020076","article-title":"Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: prospective study and meta-analysis","volume":"2","author":"Wheeler","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejim.2020.07.006_bib0064","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1097\/HJH.0000000000001078","article-title":"The association between blood pressure and lipid levels in Europe: European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice","volume":"34","author":"Borghi","year":"2016","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2020.07.006_bib0065","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.1742-1241.2009.02263.x","article-title":"The association between serum uric acid level and coronary artery disease","volume":"64","author":"Sinan Deveci","year":"2010","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ejim.2020.07.006_bib0066","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1016\/j.ijcard.2013.06.067","article-title":"The association between hyperuricemia, left atrial size and new-onset atrial fibrillation","volume":"168","author":"Chao","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0067","doi-asserted-by":"crossref","first-page":"19","DOI":"10.6061\/clinics\/2013(01)OA04","article-title":"The relationship between hyperuricemia and the risk of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with relatively normal serum creatinine","volume":"68","author":"Liu","year":"2013","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.ejim.2020.07.006_bib0068","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.STR.0000221716.55088.d4","article-title":"Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study","volume":"37","author":"Bos","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.ejim.2020.07.006_bib0069","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/CIRCHEARTFAILURE.108.797662","article-title":"Hyperuricemia and incident heart failure","volume":"2","author":"Krishnan","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ejim.2020.07.006_bib0070","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/HJH.0b013e328365b916","article-title":"Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study","volume":"32","author":"Cicero","year":"2014","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2020.07.006_bib0071","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.atherosclerosis.2013.11.051","article-title":"Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies","volume":"232","author":"Li","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2020.07.006_bib0072","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","article-title":"Uric acid and risk of heart failure: a systematic review and meta-analysis","volume":"16","author":"Huang","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2020.07.006_bib0073","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s00380-016-0893-z","article-title":"Are atherosclerotic risk factors associated with a poor prognosis in patients with hyperuricemic acute heart failure? The evaluation of the causal dependence of acute heart failure and hyperuricemia","volume":"32","author":"Okazaki","year":"2017","journal-title":"Heart Vessels"},{"key":"10.1016\/j.ejim.2020.07.006_bib0074","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejim.2019.11.003","article-title":"Increased serum uric acid level predicts poor prognosis in mildly severe chronic heart failure with reduced ejection fraction. An analysis from the MECKI score research group","volume":"72","author":"Piepoli","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2020.07.006_bib0075","doi-asserted-by":"crossref","first-page":"H1123","DOI":"10.1152\/ajpheart.00533.2015","article-title":"Relationship of hyperuricemia with mortality in heart failure patients with preserved ejection fraction","volume":"309","author":"Shimizu","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0076","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1067\/mhj.2002.122122","article-title":"Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy","volume":"143","author":"Cicoira","year":"2002","journal-title":"Am Heart J"},{"key":"10.1016\/j.ejim.2020.07.006_bib0077","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1253\/circj.70.1006","article-title":"Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in patients with congestive heart failure","volume":"70","author":"Sakai","year":"2006","journal-title":"Circ J"},{"key":"10.1016\/j.ejim.2020.07.006_bib0078","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/ajh\/hpw159","article-title":"Uric acid and new onset left ventricular hypertrophy: findings from the PAMELA population","volume":"30","author":"Cuspidi","year":"2017","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ejim.2020.07.006_bib0079","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/01.HYP.0000161184.10873.ea","article-title":"Serum uric acid and target organ damage in primary hypertension","volume":"45","author":"Viazzi","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2020.07.006_bib0080","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s13075-015-0842-8","article-title":"Gout, not hyperuricemia alone, impairs left ventricular diastolic function","volume":"17","author":"Lin","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ejim.2020.07.006_bib0081","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2310\/JIM.0b013e318214ebaf","article-title":"Elevated serum uric acid predicts angiographic impaired reperfusion and 1-year mortality in ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention","volume":"59","author":"Basar","year":"2011","journal-title":"J Investig Med"},{"key":"10.1016\/j.ejim.2020.07.006_bib0082","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1161\/HYPERTENSIONAHA.116.08436","article-title":"Uric acid is associated with inflammation, coronary microvascular dysfunction, and adverse outcomes in postmenopausal women","volume":"69","author":"Prasad","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2020.07.006_bib0083","doi-asserted-by":"crossref","first-page":"e6565","DOI":"10.1097\/MD.0000000000006565","article-title":"Asymptomatic hyperuricemia is independently associated with coronary artery calcification in the absence of overt coronary artery disease: a single-center cross-sectional study","volume":"96","author":"Kim","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejim.2020.07.006_bib0084","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.atherosclerosis.2018.02.014","article-title":"Elevated serum uric acid predicts the development of moderate coronary artery calcification independent of conventional cardiovascular risk factors","volume":"272","author":"Jun","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ejim.2020.07.006_bib0085","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1111\/jcmm.14337","article-title":"Longitudinal association between serum uric acid levels and multiterritorial atherosclerosis","volume":"23","author":"Song","year":"2019","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.ejim.2020.07.006_bib0086","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/j.ajkd.2010.01.019","article-title":"Association of uric acid with change in kidney function in healthy normotensive individuals","volume":"56","author":"Bellomo","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejim.2020.07.006_bib0087","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1093\/ndt\/gfq740","article-title":"Serum uric acid is a GFR-independent long-term predictor of acute and chronic renal insufficiency: the Jerusalem Lipid Research Clinic cohort study","volume":"26","author":"Ben-Dov","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2020.07.006_bib0088","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1681\/ASN.2004030208","article-title":"Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study","volume":"16","author":"Domrongkitchaiporn","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0089","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1093\/ndt\/gfu256","article-title":"A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population","volume":"29","author":"Kamei","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ejim.2020.07.006_bib0090","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1681\/ASN.2008010080","article-title":"Elevated uric acid increases the risk for kidney disease","volume":"19","author":"Obermayr","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0091","doi-asserted-by":"crossref","first-page":"e76827","DOI":"10.1371\/journal.pone.0076827","article-title":"Serum uric acid and chronic kidney disease: the role of hypertension","volume":"8","author":"Sedaghat","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ejim.2020.07.006_bib0092","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1681\/ASN.2007101075","article-title":"Uric acid and incident kidney disease in the community","volume":"19","author":"Weiner","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0093","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2337\/dc10-0227","article-title":"High-normal serum uric acid increases risk of early progressive renal function loss in type 1 diabetes: results of a 6-year follow-up","volume":"33","author":"Ficociello","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2020.07.006_bib0094","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2337\/dc11-1346","article-title":"Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function","volume":"35","author":"Zoppini","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2020.07.006_bib0095","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.ajkd.2007.05.013","article-title":"Relationship of uric acid with progression of kidney disease","volume":"50","author":"Chonchol","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejim.2020.07.006_bib0096","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/archinternmed.2008.605","article-title":"Risk factors for end-stage renal disease: 25-year follow-up","volume":"169","author":"Hsu","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2020.07.006_bib0097","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0272-6386(04)00934-5","article-title":"Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort","volume":"44","author":"Iseki","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejim.2020.07.006_bib0098","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1111\/j.1600-6143.2011.03613.x","article-title":"Association of serum uric acid with graft survival after kidney transplantation: a time-varying analysis","volume":"11","author":"Haririan","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ejim.2020.07.006_bib0099","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/TP.0b013e3181c73c18","article-title":"The independent association between serum uric acid and graft outcomes after kidney transplantation","volume":"89","author":"Haririan","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.ejim.2020.07.006_bib0100","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12882-018-0970-x","article-title":"Preoperative serum uric acid predicts incident acute kidney injury following cardiac surgery","volume":"19","author":"Kaufeld","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0101","doi-asserted-by":"crossref","first-page":"302 e917","DOI":"10.1016\/j.amjmed.2011.06.021","article-title":"Elevated uric acid increases the risk for acute kidney injury","volume":"125","author":"Lapsia","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.ejim.2020.07.006_bib0102","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.amjhyper.2007.08.010","article-title":"Mild hyperuricemia and subclinical renal damage in untreated primary hypertension","volume":"20","author":"Viazzi","year":"2007","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ejim.2020.07.006_bib0103","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10741-019-09869-z","article-title":"Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure","volume":"25","author":"Borghi","year":"2020","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ejim.2020.07.006_bib0104","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.jacc.2008.01.068","article-title":"Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study","volume":"51","author":"Hare","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0105","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","article-title":"Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: the Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study","volume":"131","author":"Givertz","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2020.07.006_bib0106","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"pdated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2020.07.006_bib0107","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1038\/ki.1996.268","article-title":"Renal effects of angiotensin II receptor blockade in normotensive subjects","volume":"49","author":"Burnier","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2020.07.006_bib0108","series-title":"Allopurinol tablets","year":"2018"},{"key":"10.1016\/j.ejim.2020.07.006_bib0109","series-title":"Adenuric (febuxostat) film-coated tablets","year":"2018"},{"key":"10.1016\/j.ejim.2020.07.006_bib0110","series-title":"ULORIC (febuxostat) tablet for oral use","year":"2018"},{"key":"10.1016\/j.ejim.2020.07.006_bib0111","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1136\/annrheumdis-2019-215315","article-title":"2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout","volume":"79","author":"Richette","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2020.07.006_bib0112","first-page":"983","article-title":"Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis","volume":"20","author":"Borghi","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.ejim.2020.07.006_bib0113","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/jamainternmed.2014.1427","article-title":"Allopurinol overuse in asymptomatic hyperuricemia: a teachable moment","volume":"174","author":"Carnovale","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ejim.2020.07.006_bib0114","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2020.07.006_bib0115","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejim.2020.01.001","article-title":"Management of hyperuricemia in asymptomatic patients: a critical appraisal","volume":"74","author":"Brucato","year":"2020","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2020.07.006_bib0116","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1523-1755.2004.00729.x","article-title":"Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension","volume":"66","author":"Feig","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.ejim.2020.07.006_bib0117","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1001\/jama.300.8.924","article-title":"Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial","volume":"300","author":"Feig","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2020.07.006_bib0118","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1161\/HYPERTENSIONAHA.112.196980","article-title":"Uric acid reduction rectifies prehypertension in obese adolescents","volume":"60","author":"Soletsky","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2020.07.006_bib0119","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1161\/HYPERTENSIONAHA.114.03953","article-title":"Allopurinol initiation and change in blood pressure in older adults with hypertension","volume":"64","author":"Beattie","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2020.07.006_bib0120","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2215\/CJN.10771016","article-title":"Effect of uric acid lowering on renin-angiotensin-system activation and ambulatory BP: a randomized controlled trial","volume":"12","author":"McMullan","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0121","doi-asserted-by":"crossref","first-page":"610-9 e1","DOI":"10.1016\/j.jash.2015.05.009","article-title":"The effect of the addition of allopurinol on blood pressure control in African Americans treated with a thiazide-like diuretic","volume":"9","author":"Segal","year":"2015","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.ejim.2020.07.006_bib0122","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006683","article-title":"Effect of febuxostat on ambulatory blood pressure in subjects with hyperuricemia and hypertension: a phase 2 randomized placebo-controlled study","volume":"6","author":"Gunawardhana","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2020.07.006_bib0123","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejim.2020.07.006_bib0124","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1751-7176.2012.00701.x","article-title":"Effect of allopurinol on blood pressure: a systematic review and meta-analysis","volume":"15","author":"Agarwal","year":"2013","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.ejim.2020.07.006_bib0125","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/07853890.2016.1243803","article-title":"Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis","volume":"49","author":"Qu","year":"2017","journal-title":"Ann Med"},{"key":"10.1016\/j.ejim.2020.07.006_bib0126","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1097\/JIM.0000000000000242","article-title":"Lowering uric acid with allopurinol improves insulin resistance and systemic inflammation in asymptomatic hyperuricemia","volume":"63","author":"Takir","year":"2015","journal-title":"J Investig Med"},{"key":"10.1016\/j.ejim.2020.07.006_bib0127","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00296-016-3612-2","article-title":"Effects of febuxostat on insulin resistance and expression of high-sensitivity C-reactive protein in patients with primary gout","volume":"37","author":"Meng","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ejim.2020.07.006_bib0128","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ijo.2009.259","article-title":"Excessive fructose intake induces the features of metabolic syndrome in healthy adult men: role of uric acid in the hypertensive response","volume":"34","author":"Perez-Pozo","year":"2010","journal-title":"Int J Obes"},{"key":"10.1016\/j.ejim.2020.07.006_bib0129","first-page":"69","article-title":"Assessment of the therapeutic effect of allopurinol on patients with non-alcoholic fatty liver disease associated with hyperuricemia by cytokeratin 18","volume":"6","author":"Sedhom","year":"2016","journal-title":"J Gastrointest Dig Syst"},{"key":"10.1016\/j.ejim.2020.07.006_bib0130","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/HYPERTENSIONAHA.115.06344","article-title":"Allopurinol and cardiovascular outcomes in adults with hypertension","volume":"67","author":"MacIsaac","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2020.07.006_bib0131","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/01.CIR.0000017502.58595.ED","article-title":"Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies","volume":"105","author":"Doehner","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2020.07.006_bib0132","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1161\/01.CIR.0000022140.61460.1D","article-title":"Allopurinol improves endothelial dysfunction in chronic heart failure","volume":"106","author":"Farquharson","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2020.07.006_bib0133","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.jacc.2010.12.052","article-title":"Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris","volume":"58","author":"Rajendra","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0134","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1755-5922.2011.00277.x","article-title":"Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta\u2010analysis","volume":"30","author":"Higgins","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.ejim.2020.07.006_bib0135","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13075-016-1111-1","article-title":"Allopurinol reduces the risk of myocardial infarction (MI) in the elderly: a study of Medicare claims","volume":"18","author":"Singh","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ejim.2020.07.006_bib0136","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12883-016-0692-2","article-title":"Allopurinol and the risk of stroke in older adults receiving Medicare","volume":"16","author":"Singh","year":"2016","journal-title":"BMC Neurol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0137","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCHEARTFAILURE.109.868604","article-title":"Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study","volume":"3","author":"Ogino","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ejim.2020.07.006_bib0138","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","article-title":"Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy","volume":"40","author":"Kojima","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2020.07.006_bib0139","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.118.033992","article-title":"Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2020.07.006_bib0140","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1536\/ihj.17-560","article-title":"Randomized trial of effect of urate-lowering agent febuxostat in chronic heart failure patients with hyperuricemia (LEAF-CHF)","volume":"59","author":"Yokota","year":"2018","journal-title":"Int Heart J"},{"key":"10.1016\/j.ejim.2020.07.006_bib0141","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2215\/CJN.11451210","article-title":"A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function","volume":"6","author":"Kanbay","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0142","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40261-015-0349-8","article-title":"Effect of febuxostat, a xanthine oxidase inhibitor, on cardiovascular risk in hyperuricemic patients with hypertension: a prospective, open-label, pilot study","volume":"35","author":"Tani","year":"2015","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ejim.2020.07.006_bib0143","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.2215\/CJN.01580210","article-title":"Effect of allopurinol in chronic kidney disease progression and cardiovascular risk","volume":"5","author":"Goicoechea","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0144","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3899\/jrheum.131159","article-title":"Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia","volume":"41","author":"Levy","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ejim.2020.07.006_bib0145","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/annrheumdis-2015-209046","article-title":"Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure","volume":"76","author":"Singh","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ejim.2020.07.006_bib0146","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1053\/j.ajkd.2015.05.017","article-title":"Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial","volume":"66","author":"Sircar","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ejim.2020.07.006_bib0147","doi-asserted-by":"crossref","first-page":"e16311","DOI":"10.1097\/MD.0000000000016311","article-title":"Effects of febuxostat on renal function in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"98","author":"Lin","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ejim.2020.07.006_bib0148","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41581-019-0174-z","article-title":"The case for uric acid-lowering treatment in patients with hyperuricaemia and CKD","volume":"15","author":"Sato","year":"2019","journal-title":"Nat Rev Nephrol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520302909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620520302909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:32:37Z","timestamp":1760607157000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620520302909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":148,"alternative-id":["S0953620520302909"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2020.07.006","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2020.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}